Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase 3-beta-1 (TOP3B) is a unique metazoan enzyme in the type IA family, notable for its ability to act on both DNA and RNA substrates. It resolves DNA/RNA topological entanglements—unknotting, decatenating, and resolving supercoils—by transiently breaking and rejoining single-stranded DNA or RNA, permitting the passage of another strand. Unlike most topoisomerases, TOP3B also participates robustly in RNA metabolism, including the disassembly of R-loops, regulation of mRNA translation, and association with the scaffold protein TDRD3 (which recruits TOP3B to specific chromatin or RNA sites). Its physiological importance in genome stability, neurodevelopment, and aging is well established. Mutations in TOP3B are linked to neurodevelopmental disorders, and its diverse nucleic acid substrate recognition makes it an emerging target for antiviral and anticancer drug discovery.
For theoretical/topoisomerase-directed small molecules: Inhibition of TOP3B would block relaxation of DNA/RNA structures, increase accumulation of R-loops and/or DNA damage, leading to cytostatic or cytotoxic effects (extrapolated from general topoisomerase mechanisms)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase 3-beta-1 (TOP3B).